Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Botryosphaeran is an exocellular (1→3)(1→6)-β-D-glucan produced by the fungus *Botryosphaeria rhodina* MAMB-05. It is a fungal polysaccharide that has demonstrated antiproliferative and pro-apoptotic effects in preclinical models, specifically in MCF-7 breast cancer cells. The mechanism of action involves the activation of the AMP-activated protein kinase (AMPK) and the Forkhead transcription factor FOXO3a, which subsequently increases the expression of pro-apoptotic proteins such as Bax and caspase-3. Additionally, botryosphaeran treatment leads to the inhibition of p70S6K and the induction of oxidative stress, contributing to its antitumor activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on botryosphaeran.